Glenmark Specialty

Glenmark Specialty S.A., a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited (Glenmark), is a research-driven global pharmaceutical company with operations in generics, specialty, and over-the-counter (OTC) businesses across more than 80 countries. Glenmark's key therapeutic areas are respiratory, dermatology, and oncology. It ranks among the top 50 generic and biosimilar companies globally (Top 50 Companies Ranking 2020 by Generics Bulletin from Informa). Glenmark Specialty S.A. (Switzerland) received FDA approval for its New Drug Application (NDA) for Ryaltris™, an innovative fixed-dose (metered) prescription combination drug product nasal spray for the treatment of symptoms of seasonal allergic rhinitis.